key: cord-1044127-7d9i8gb0 authors: Tabarsi, Payam; Afzal, Golnaz; Eskandari, Raha; Dastan, Farzaneh title: Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab date: 2021-03-03 journal: Tanaffos DOI: nan sha: c7655f8f16b3366cce17c6bf4e5e1bd40544d7cd doc_id: 1044127 cord_uid: 7d9i8gb0 nan Daneshvari Hospital, Tehran, Iran, with the presentation of fever, chills, anorexia, fatigue, cough, shortness of breath, and pleuritic chest pain. Reverse transcription-polymerase chain reaction (RT-PCR) and chest computed tomography (CT) previously performed were negative for coronavirus disease 2019 (COVID-19). Three weeks earlier, the case was confirmed to have COVID-19 by a positive RT-PCR test and bilateral chest infiltrate and was treated with lopinavir/ritonavir in accordance with the national guidelines. Subsequently, the case was discharged with an acceptable clinical condition and a negative RT-PCR test. Laboratory parameters and clinical characteristics are reported in tables 1 and 2, respectively. Pulmonary CT angiography revealed positive results for pulmonary embolism. The patient received therapeutic heparin (80 units/kg intravenous bolus, followed by a continuous infusion of 18 units/kg/hour) and was closely monitored for hemodynamic instability. Over the next 48 hours, the patient's symptoms did not improve, and he had elevated erythrocyte sedimentation rate (ESR), D-dimer, and C-reactive protein (CRP) levels, with no other risk factors for pulmonary embolism, indicating that a COVID-19-related hypercoagulable state was the possible reason for pulmonary vasculature thrombosis. The level of interleukin 6 (IL-6) was observed to be high (Table 1) . Based on clinical and laboratory features, the patient was diagnosed with a delayed postviral COVID-19 cytokine release storm. At this time, tocilizumab was considered the best treatment choice. Therefore, the patient was treated with a single dose of 400-mg tocilizumab (Actemra; Hoffmann-La Roche Limited). The patient was discharged from the hospital with a stable condition 3 days later ( Table 2) . He was followed up until June 20, 2020, to be monitored for potential symptom relapse, and there were no episodes of symptom relapse or need for hospital readmission during 3 months. On March 29, 2020, a 49-year-old male case was referred to an emergency department with 5 days of fever, dry cough, and dyspnea on exertion. The patient had no underlying diseases or history of medicine usage; however, he was confirmed to have COVID-19 by a positive RT-PCR test one month ago and was treated with an antiviral drug (i.e., favipiravir). Laboratory measurements showed elevated white blood cell, CRP, ESR, and IL-6 levels ( Table 1) . The patient was diagnosed with a delayed postviral COVID-19 cytokine release storm. Tocilizumab (Actemra; Hoffmann-La Roche Limited) was infused as a single dose of 400 mg over 2 hours. The patient was discharged from the hospital on the 4 th day with oxygen saturation of 95% and an acceptable clinical condition ( Herein, we reported two cases of late systemic inflammatory responses induced by COVID-19 after several weeks. These responses were characterized by the release of IL-6, which induced a cytokine storm. Certain reports have shown that severe acute respiratory syndrome coronavirus 2 binds to alveolar epithelial cells and activates the innate and adaptive immune systems, resulting in the release of numerous cytokines (1). In the current cases, we faced a delayed cytokine storm, which occurred several weeks after infection with COVID-19. High serum levels of IL-6 in COVID-19 can occur in later stages (2) . The interaction of adaptive and innate immune responses might temporarily decrease the level of virus ribonucleic acid (RNA). However, if the virus is not completely cleared, late mast-cell activation leads to the release of pro-inflammatory cytokines, such as IL-6 (3). Another study observed the clinical course of the multisystem inflammatory syndrome, which was treated with IL-6 inhibitors (4). Lai et al. reported the patients with COVID-19 whose conditions deteriorated suddenly in the later stages of the disease or in the process of recovery (5 (7). Other studies described the overproduction of pro-inflammatory cytokines in patients with COVID-19, which induced localized microvascular inflammation. This process leads to an increased risk of vascular hyperpermeability and prothrombotic conditions (8, 9) . Likewise, the finding of raised D-dimer concentrations as a prognostic feature in severe COVID-19 pneumonia indicated the activation of the coagulation pathways (10, 11) . One treatment option might be IL-6 inhibition by tocilizumab (12, 13) . Herein, we have reported the successful treatment of two patients with late-onset hyperactivated immunity pathways several weeks after infection with COVID-19 and achieved rapid control of hyperinflammation by blocking the IL-6 receptor using tocilizumab. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer Interleukin-6 in Covid-19: A systematic review and meta-analysis Mast cells and influenza a virus: association with allergic responses and beyond Multisystem Inflammatory Syndrome in U.S. Children and Adolescents Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Cytokine responses in severe acute respiratory syndrome coronavirusinfected macrophages in vitro: possible relevance to pathogenesis Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation COVID-19 cytokine storm: the interplay between inflammation and coagulation Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Acute Pulmonary Embolism in Patients with COVID-19 at CT Angiography and Relationship to d-Dimer Levels Tocilizumab administration in a refractory case of COVID-19 Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial